Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones
Featured News & Press Releases
Sep 27, 2022: Iveric Bio to present top-line results for avacincaptad pegol from phase 3 GATHER2 clinical trial in geographic atrophy at AAO 2022 Annual Meeting
Sep 26, 2022: EC approves Alexion’s Ultomiris for generalised myasthenia gravis
Sep 22, 2022: CANbridge Pharmaceuticals data on CAN106 to be presented at two conferences
Sep 09, 2022: InflaRx to present at upcoming scientific and investor conferences
Sep 08, 2022: Inflarx announces vilobelimab phase III results in critically ill covid-19 patients published in The Lancet Respiratory Medicine
Sep 06, 2022: Iveric Bio announces positive topline data from Zimura GATHER2 phase 3 clinical trial in geographic atrophy
Aug 29, 2022: Alnylam eports positive results from phase 2 study of investigatiol Cemdisiran for the treatment of IgA Nephropathy
Aug 26, 2022: Kira Pharmaceuticals to present new preclinical data on lead asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference
Aug 25, 2022: Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis
Aug 24, 2022: Amgen reports positive data from Phase III trial of biosimilar for PNH
Aug 10, 2022: Anti-C5 recycling antibody crovalimab obtains priority review in chi for the treatment of paroxysmal nocturl hemoglobinuria
Aug 03, 2022: Immubs announces US FDA approval for a phase 1 clinical trial
Aug 01, 2022: Akari Therapeutics rrows pipeline focus
Jul 28, 2022: Kira Pharmaceuticals receives FDA Orphan Drug Desigtion for KP104, a bifunctiol antibody fusion protein, for the treatment of Paroxysmal Nocturl Hemoglobinuria
Jul 28, 2022: Akari Therapeutics announces positive results from recent pre-clinical studies of investigatiol PASylated nomacopan that support the potential to advance research toward IND/IMPD for clinical trials in geographic atrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Discontinued Products, 2022